Jinxin Fertility appointed Li Yuan, an authoritative reproductive medicine expert, as chief medical officer

Recently, Jinxin Reproductive Medical Group Co., Ltd. (stock code: 1951. HK; referred to as "Jinxin Fertility") officially announced that Professor Li Yuan, an authoritative reproductive medicine expert, was specially appointed as the chief medical officer of the company.

Dong Yang, CEO of Jinxin Fertility, said: "This appointment will open a new chapter for Jinxin Fertility. Professor Li Yuan is an outstanding leader in the field of reproductive medicine, with a series of achievements in scientific research innovation and medical quality management. It is believed that the joining of Professor Li Yuan will inject new vitality into Jinxin Fertility. In the future, we will continue to strengthen high-quality talent, medical, management and service capabilities, and continue to meet the growing market demand by providing high-success quality services, helping to achieve more happy families. ”

As an outstanding talent of the new century of the Ministry of Education, Professor Li Yuan has been engaged in reproductive medicine since 1994 and is one of the first batch of doctors in reproductive medicine in China. Whether in ivf clinical or laboratory work that is compared to the first "home" of embryos, Professor Li Yuan is known for her proficiency in finding problems and solving problems, and has successively created a number of "first" records - not only for the first LH level-based antagonist ovulation promotion program by industry experts as "the first person in China's antagonist program", but also the founder of the first case of vitrification frozen egg technology and the first immature ovulation in vitro mature IVF technology.

At present, Professor Li Yuan has published more than 130 articles in domestic and foreign journals, has more than 10 patents, and undertaken 8 projects such as the National 973 Program and the National Natural Science Foundation of China. Not only that, Professor Li Yuan has also won a number of national and provincial science and technology awards. It is worth mentioning that the "Human Assisted Reproduction Laboratory Technology" edited by Professor Li Yuan in 2008 was "all the rage" and can be called a "must-read textbook" for laboratory personnel to enter the industry.

Before joining Jinxin Reproduction, Professor Li Yuan served as the director of the laboratory and the assistant dean of the Affiliated Reproductive Hospital of Shandong University, and was the open disciple of Academician Chen Zijiang. During the period, by improving the IVF laboratory operation process and establishing a standardized quality control system, Professor Li Yuan led the team to take the lead in completing the ISO 9001 certification of the full treatment cycle of IVF in China, improving the success rate of patient treatment and establishing a good reputation for the hospital, thus driving the number of IVF treatment cycles in the hospital to achieve a jump.

At the end of 2011, Professor Li Yuan entered Beijing Chaoyang Hospital as a special talent. During the period, Professor Li Yuan presided over the reconstruction of the medical team and the IVF process, helped the hospital to successfully obtain IVF qualifications, and spent 8 years to make the clinical scale of the hospital's reproductive center rank among the top three in Beijing; at the same time, Professor Li Yuan helped to improve the level of diagnosis and treatment of the medical team on the one hand, and on the other hand, paid attention to cultivating the sense of team service, under her leadership, the team established effective solutions for infertility patients with difficult infertility such as repeated IVF treatment failure and repeated pregnancy loss, and a large number of patients were able to successfully conceive and give birth smoothly. Consistent with the dramatic increase in IVF success rates in hospitals, patient satisfaction continues to rise.

Over the years, through specialty alliances and multidisciplinary cooperation, Professor Li Yuan has been widely praised among doctors. In addition to the clinic, Professor Li Yuan also takes the way of advancing with the times to maintain interaction with the majority of patients and is deeply loved - through new media platforms such as WeChat public account and headline number "Fertility Expert Li Yuan", Douyin number "Eugenic Baby Li Yuan Said" to carry out knowledge science popularization and health education for patients, and the total number of fans on each platform has reached more than 700,000 people.

It is understood that after joining Jinxin Reproduction, Professor Li Yuan will continue to further strengthen science popularization and education through various new media, and popularize reproductive health knowledge to thousands of households. At the same time, Professor Li Yuan will be mainly responsible for the supervision of the Group's medical quality, and preside over the management of medical services and personnel training. Professor Li Yuan will also take turns in the hospitals under the Group to bring the gospel to patients across the country. "It is a pleasure and honor to join Jinxin Reproduction. It is expected that by creating a higher level of medical service personnel echelon, helping to strengthen medical technology innovation, and better serving more families in need, we will contribute to the development of China's reproductive health cause. Professor Li Yuan said.

Jinxin Fertility landed on the main board of the Hong Kong Stock Exchange in June 2019, becoming the leading Chinese medical service stock in the Hong Kong capital market, the "first share of assisted reproductive health care", and was awarded the "Best IPO in China" in the Hong Kong market in 2019 by Treasury Magazine. From 2020 to 2021, Jinxin Fertility has successively won the honor of "Most Respected Enterprise" by the well-known international authoritative financial magazine "Institutional Investor". As an international professional service institution in the field of assisted reproductive medicine, Jinxin Fertility owns and operates Chengdu Xiyuan Women's Hospital, Shenzhen Zhongshan Urology Hospital, Wuhan Jinxin Integrated Traditional Chinese and Western Medicine Obstetrics and Gynecology Hospital in China, HRC Assisted Reproduction Center in the United States, and Jinrui Medical Center (HRC Asian Reproductive Medicine Center) in Laos, which is currently the largest non-public assisted reproductive medical group with global influence in China.

【Author】 Zhao Binghui

【Source】 Southern Press Media Group South + client

Source: South+ - Create more value